One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis

Autor: Kamyar Kalantar-Zadeh, Jessica Kendrick, Linda H. Ficociello, Vidhya Parameswaran, Shannon Davis, Claudy Mullon, Robert J. Kossmann, Norma J. Ofsthun
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Sucrose
Time Factors
Kidney Disease
medicine.medical_treatment
030232 urology & nephrology
Medicine (miscellaneous)
Ferric Compounds
Cohort Studies
Hyperphosphatemia
0302 clinical medicine
Renal Insufficiency
Chelating Agents
Nutrition and Dietetics
Medical record
Phosphorus
Middle Aged
Urology & Nephrology
Drug Combinations
Treatment Outcome
Nephrology
Pill
6.1 Pharmaceuticals
Female
Hemodialysis
Adult
medicine.medical_specialty
medicine.drug_class
Clinical Sciences
chemistry.chemical_element
Nutritional Status
Pharmacy
Article
Phosphates
Medication Adherence
03 medical and health sciences
Renal Dialysis
Clinical Research
Internal medicine
medicine
Humans
Medical prescription
Aged
030109 nutrition & dietetics
business.industry
Evaluation of treatments and therapeutic interventions
medicine.disease
Phosphate binder
chemistry
business
Zdroj: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, vol 29, iss 5
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
Popis: OBJECTIVE:The high pill burden of many phosphate binders (PBs) may contribute to increased prevalence of hyperphosphatemia and poor nutritional status observed among patients undergoing maintenance hemodialysis therapy. We examined the real-world effectiveness of sucroferric oxyhydroxide (SO), a PB with low pill burden, in managing serum phosphorus in patients with prevalent hemodialysis over a 1-year period. DESIGN:Historical cohort analyses of de-identified electronic medical records. SUBJECTS:In-center hemodialysis patients switched from another PB to SO therapy as part of routine care with 12months of uninterrupted SO prescriptions recorded, and documented serum phosphorus levels were eligible for inclusion. Clinical data were extracted from a pharmacy service, FreseniusRx, database and Fresenius Kidney Care clinical data warehouse. MAIN OUTCOME MEASURES:Comparisons were made between the 91-day period before SO initiation (i.e., baseline) and the 4 consecutive 91-day intervals of SO treatment (Q1-Q4). Clinical measures included achievement of target phosphorus levels (≤5.5mg/dL) and mean number of PB pills/day. RESULTS:Among 530 analyzed patients, the proportion achieving target serum phosphorus levels increased by >100% 1year after switching to SO therapy, that is, from 17.7% at baseline to 24.5%, 30.5%, 36.4%, and 36.0% at Q1 through Q4, respectively (P 
Databáze: OpenAIRE
Externí odkaz: